Development of Serum Glycoproteomic Profiling Technique; Simultaneous Identification of Glycosylation Sites and Site-Specific Quantification of Glycan Structure Changes

Koji Ueda, Sachiko Takami, Naomi Saichi, Yataro Daigo, Nobuhisa Ishikawa, Nobuoki Kohno, Masaru Katsumata, Akio Yamane, Minoru Ota, Takaaki Sato,

Molecular & Cellular Proteomics · 2010 · 68 citations · 8 references

DOIFull text

Open access

Concepts

Abstract

Characterization and interpretation of disease-associated alterations of protein glycosylation are the central aims of the emerging glycoproteomics projects, which are expected to lead to more sensitive and specific diagnosis and improve therapeutic outcomes for various diseases. Here we report a new approach to identify carbohydrate-targeting serum biomarkers, termed isotopic glycosidase elution and labeling on lectin-column chromatography (IGEL). This technology is based on glycan structure-specific enrichment of glycopeptides by lectin-column chromatography and site-directed tagging of N-glycosylation sites by 18O during the elution with N-glycosidase. The combination of IGEL with 8-plex isobaric tag for relative and absolute quantitation (iTRAQ) stable isotope labeling enabled us not only to identify N-glycosylation sites effectively but also to compare glycan structures on each glycosylation site quantitatively in a single LC/MS/MS analysis. We applied this method to eight sera from lung cancer patients and controls, and finally identified 107 glycopeptides in their sera, including A2GL_Asn151, A2GL_Asn290, CD14_Asn132, CO8A_Asn417, C163A_Asn64, TIMP1_Asn30, and TSP1_Asn1049 which showed the significant change of the affinity to Concanavalin A (ConA) lectin between the lung cancer samples and the controls (p < 0.05 and more than twofold change). These screening results were further confirmed by the conventional lectin-column chromatography and immunoblot analysis using additional serum samples. Our novel methodology, which should be valuable for diverse biomarker discoveries, can provide high-throughput and quantitative profiling of glycan structure alterations. Characterization and interpretation of disease-associated alterations of protein glycosylation are the central aims of the emerging glycoproteomics projects, which are expected to lead to more sensitive and specific diagnosis and improve therapeutic outcomes for various diseases. Here we report a new approach to identify carbohydrate-targeting serum biomarkers, termed isotopic glycosidase elution and labeling on lectin-column chromatography (IGEL). This technology is based on glycan structure-specific enrichment of glycopeptides by lectin-column chromatography and site-directed tagging of N-glycosylation sites by 18O during the elution with N-glycosidase. The combination of IGEL with 8-plex isobaric tag for relative and absolute quantitation (iTRAQ) stable isotope labeling enabled us not only to identify N-glycosylation sites effectively but also to compare glycan structures on each glycosylation site quantitatively in a single LC/MS/MS analysis. We applied this method to eight sera from lung cancer patients and controls, and finally identified 107 glycopeptides in their sera, including A2GL_Asn151, A2GL_Asn290, CD14_Asn132, CO8A_Asn417, C163A_Asn64, TIMP1_Asn30, and TSP1_Asn1049 which showed the significant change of the affinity to Concanavalin A (ConA) lectin between the lung cancer samples and the controls (p < 0.05 and more than twofold change). These screening results were further confirmed by the conventional lectin-column chromatography and immunoblot analysis using additional serum samples. Our novel methodology, which should be valuable for diverse biomarker discoveries, can provide high-throughput and quantitative profiling of glycan structure alterations. Glycan structure variations often show highly organ-specific manners (1.Wollscheid B. Bausch-Fluck D. Henderson C. O'Brien R. Bibel M. Schiess R. Aebersold R. Watts J.D. Nat. Biotechnol. 2009; 27: 378-386Crossref PubMed Scopus (429) Google Scholar, 2.Brown S.M. Smith D.M. Alt N. Thorpe S.R. Baynes J.W. Ann. N.Y. Acad. Sci. 2005; 1043: 817-823Crossref PubMed Scopus (29) Google Scholar), as well as those manners that correlate with diverse disease states, (3.Tissot B. North S.J. Ceroni A. Pang P.C. Panico M. Rosati F. Capone A. Haslam S.M. Dell A. Morris H.R. FEBS Lett. 2009; 583: 1728-1735Crossref PubMed Scopus (72) Google Scholar, 4.Bos P.D. Zhang X.H. Nadal C. Shu W. Gomis R.R. Nguyen D.X. Minn A.J. van de Vijver M.J. Gerald W.L. Foekens J.A. Massague J. Nature. 2009; 459: 1005-1009Crossref PubMed Scopus (1332) Google Scholar) e.g., cancer and inflammation. Thus, the carbohydrates are currently attracting a great deal of attention as specific targets of cancer biomarkers and therapy (5.Kawasaki N. Itoh S. Hashii N. Takakura D. Qin Y. Huang X. Yamaguchi T. Biol, Pharm. Bull. 2009; 32: 796-800Crossref PubMed Scopus (58) Google Scholar). In fact, certain changes of glycan structures are already in clinical use as serum biomarkers, such as AFP-L3 (6.Ludwig J.A. Weinstein J.N. Nat. Rev. Cancer. 2005; 5: 845-856Crossref PubMed Scopus (1346) Google Scholar), and glycosylation at the specific site of therapeutic antibody proved to be essential for its therapeutic effect (7.Suzuki E. Niwa R. Saji S. Muta M. Hirose M. Iida S. Shiotsu Y. Satoh M. Shitara K. Kondo M. Toi M. Clin. Cancer Res. 2007; 13: 1875-1882Crossref PubMed Scopus (95) Google Scholar). Advances in proteomic technologies and analysis have stimulated a great interest in application of MS to identify glycosylation sites (8.Kaji H. Saito H. Yamauchi Y. Shinkawa T. Taoka M. Hirabayashi J. Kasai K. Takahashi N. Isobe T. Nat. Biotechnol. 2003; 21: 667-672Crossref PubMed Scopus (572) Google Scholar, 9.Kaji H. Yamauchi Y. Takahashi N. Isobe T. Nat. Protoc. 2006; 1: 3019-3027Crossref PubMed Scopus (137) Google Scholar) or analyze glycan structures (10.Morelle W. Faid V. Chirat F. Michalski J.C. Methods Mol. Biol. 2009; 534: 5-21PubMed Google Scholar, 11.Li B. An H.J. Hedrick J.L. Lebrilla C.B. Methods Mol. Biol. 2009; 534: 133-145PubMed Google Scholar) from various biological specimens, but the comprehensive techniques which allow quantitative profiling of glycan structures on each glycosylation site have not been developed. The two major issues facing recent glycoproteomic studies are the difficulties in glycopeptide-specific enrichment tools involving lectin-column chromatography and the detection of glycopeptides in mass spectrometers. In the conventional lectin-column chromatography experiments, glycoprotein enrichment from complicated protein mixtures, such as human sera, resulted in a heavy contamination of hapten sugar, salts, and nonspecific proteins caused by protein-protein interactions of serum proteins (12.Jin S. Cheng Y. Reid S. Li M. Wang B. Med. Res. Rev. 2009; 30: 171-257Google Scholar). Even when the digested peptide mixture was subjected to the lectin-column chromatography, salt contamination and the eluting sugar-dependent biases of elution efficiency were inevitable. Moreover, the straightforward analysis of the eluted glycopeptides by MS was hardly possible without further deglycosylation and desalting steps. In this study we report our new approach for the identification of carbohydrate-targeting biomarkers, termed isotopic glycosidase elution and labeling on lectin-column chromatography (IGEL), 1The abbreviations used are:IGELisotopic glycosidase elution and labeling on lectin-column chromatographyiTRAQisobaric tag for relative and absolute quantitationCOPDchronic obstructive pulmonary diseaseIgimmunoglobulinSCXstrong cation exchange. which is based on glycan structure-specific enrichment of glycopeptides by lectin- column chromatography and site-directed labeling of N-glycosylation sites by water-18O during the elution with N-glycosidase. We combined this method with 8-plex isotobaric tag for relative and absolute quantitation (iTRAQ) labeling for relative quantification of glycopeptides and applied them to search for carbohydrate-targeting serum biomarkers in lung cancer patient sera. isotopic glycosidase elution and labeling on lectin-column chromatography isobaric tag for relative and absolute quantitation chronic obstructive pulmonary disease immunoglobulin strong cation exchange. Archived human serum samples were obtained with informed consent from 12 patients who had lung adenocarcinoma and six patients who had chronic obstructive pulmonary disease (COPD) at Hiroshima University Hospital. Serum samples as normal controls were also obtained with informed consent from six healthy volunteers who received medical examinations at Hiroshima University Hospital. Serum was collected using standard protocol from whole blood by centrifugation at 1,500 × g for 10 minutes and stored at −150°C. This study was approved by individual institutional ethical committees. Fourteen abundant proteins in serum (albumin, immunoglobulinG [IgG], antitrypsin, IgA, transferrin, haptoglobin, fibrinogen, alpha2-macroglobulin, alpha1-acid glycoprotein, IgM, apolipoprotein Al, apolipoprotein All, complement C3, and transthyretin) were removed from 40 μL of each serum sample using 4.6 × 100 mm Multiple Affinity Removal System (MARS) LC Column - Human 14 (Agilent Technologies, Santa Clara, CA) coupled with Prominence HPLC system (Shimadzu, Tokyo, Japan). The unbound fractions were directly loaded to 4.6 × 50 mm mRP-C18 column (Agilent) and desalted with the protocols recommended by the manufacturer. The eluted proteins were vacuum-dried and subjected to trypsin digestion. The dried proteins were resuspended in 50 μL of [8 mol/L Urea, 50 mmol/L ammonium bicarbonate (Sigma, St. Louis, MO)] and reduced with 10 mmol/L tris(2-carboxyethyl)phosphine (Sigma) at 37°C for 30 minutes and alkylated in 50 mmol/Liodoacetamide (Sigma) with 50 mmol/L ammonium bicarbonate for 45 minutes in the dark at 25°C. Porcine trypsin (Promega, Madison, WI) was added for a final enzyme to protein ratio of 1:20. The digestion was conducted at 37°C for 16 hours, followed by quenching the reaction with the addition of trifluoroacetic acid at the final concentration 0.4%. The digested peptides were then desalted with Oasis HLB cartridges (Waters, Milford, MA) according to the manufacturer's instructions except for the use of binding solution (0.1% trifluoroacetic acid with 2% acetonitrile) and elution solution (0.1% trifluoroacetic acid with 70% acetonitrile). The eluted peptides were vacuum-dried and subjected to 8-plex iTRAQ labeling. The dried peptides were resuspended in 30 μL of [500 mmol/L triethylammonium bicarbonate (Sigma), 50% acetonitrile, pH 8.5] and combined with a vial of 8-plex iTRAQ reagent (Applied Biosystems, Foster City, CA) that was reconstructed with 70 μL of ethanol. After incubation for two hours with gentle shaking at ambient temperature, eight samples were mixed and vacuum-dried. The iTRAQ-labeled peptides were resuspended in 500 μL of [100 mmol/L ammonium bicarbonate, 10% acetonitrile] and applied to the 1 mL polypropylene column (Qiagen, Valencia, CA) packed with 500 μL of ConA-agarose beads (Seikagaku Biobusiness Corporation, Tokyo, Japan). After 60 minutes of incubation with gentle rotation at ambient temperature, the column was washed with 1 mL of [100 mmol/L ammonium bicarbonate, 10% acetonitrile] five times and subsequently 500 μL of [100 mmol/L ammonium bicarbonate, 10% acetonitrile, 90% water (18O 98%, Wako Pure Chemical Industries, Osaka, Japan)] three times. The column was then incubated with 5 units (5 μL) of N-glycosidase F (Roche Applied Science) in 500 μL of [100 mmol/L ammonium bicarbonate, 10% acetonitrile, 90% water (18O 98%)] at 37°C for 12 hours. The eluate and additional five rinses with 500 μL of [100 mmol/M ammonium bicarbonate, 10% acetonitrile] were combined and vacuum-dried. The peptides were resuspended in 20 μL of [0.1% trifluoroacetic acid, 70% acetonitrile] and loaded to 0.2 × 200 mm MonoCap SCX column (GL Science, Tokyo, Japan) with the use of solvent A [10 mmol/L ammonium formate, 25% acetonitrile] and solvent B [1 mol/L ammonium formate, 25% acetonitrile] at a flow rate of 5 μL/min. During the multistep linear gradient of solvent B 0 to 15% for 15 minutes and 15 to 100% for 5 minutes, the eluted fraction was separately collected each minute, followed by vacuum-drying. The fractions of SCX chromatography were individually analyzed with QSTAR Elite MS (Applied Biosystems) combined with UltiMate 3000 nano-flow HPLC system (DIONEX Corporation, Sunnyvale, CA). The peptides were separated on 75 μm × 150 mm l-Column (Chemicals Evaluation and Research Institute) using solvent A [0.1% formic acid, 2% acetonitrile] and solvent B [0.1% formic acid, 70% acetonitrile] with the multistep linear gradient of solvent B 5 to 45% for 65 minutes and 45 to 95% for 10 minutes at a flow rate 200 nL/min. QSTAR Elite mass spectrometer was used in standard MS/MS data-dependent acquisition mode. The 1 s survey MS spectra were collected (m/z 400–1800) followed by three MS/MS measurements on the most intense parent ions (30 counts/sec threshold, +2-+4 charge state, mass for using the manufacturer's parent ions were from MS/MS acquisition for 40 mass The was and was by the manufacturer's iTRAQ (Applied Biosystems) with the was used for the identification and relative quantification of MS were the human protein from The search were trypsin as at as and search We report only peptide with and protein with which 95% in we used protein with more than two peptide such as of and of were as in we a in to the as on The peptide identification including quantification results was the from We peptides with and and used peptides with the for the further quantification analysis. we only the and on After the and the peptides with acid and peptides on were which were expected to be from the of N-glycosylation was The of eight ions from each identified peptide was used for the quantification analysis. We the absolute of the the relative from the normal by eight by the of the from three healthy controls with and The obtained from the sample with lectin were as We further analyzed samples without lectin to relative protein eight termed as These for a protein were from the of peptide quantification to that glycan structure changes eight samples were as each of serum samples were with column and mRP-C18 column as The protein samples were resuspended with 10 μL of [8 mmol/L Urea, 50 mmol/L and with μL of the The fractions were collected in with the manufacturer's three times elution with 50 μL of the elution The 20 μL of the eluate were on 10% and a The were with antibody After incubation of the with antibody the was on using a detection Our IGEL technology major for lectin-column chromatography and mass analysis of the eluted of the IGEL method was peptides N-glycosylation sites in was directly by MS mass by of to and to be in mass the of the was more specific to the IGEL which enabled identification of glycosylation the combination with 8-plex iTRAQ labeling of peptides of lectin-column chromatography and quantitative of glycan structures on serum proteins from eight identify carbohydrate-targeting serum for lung we applied this IGEL method to eight human serum of sera from three healthy controls, two chronic obstructive pulmonary disease (COPD) and three lung cancer patients serum abundant abundant with the between serum and the 14 most abundant serum proteins were removed from sera using the Human 14 column In this of serum proteins on the was The protein rate of the desalting by mRP-C18 column chromatography was After peptides were with 8-plex iTRAQ stable isotope We the peptide labeling protocol by vial of 8-plex iTRAQ reagent to of serum peptide mixture that of and of peptides were by iTRAQ The vacuum-dried peptides were applied to the lectin-column we the efficiency of 18O in the peptides using QSTAR Elite LC/MS/MS The MS or MS/MS spectra of the identified peptide in our or from the protein were in The was in the two in the F reaction was conducted in as a or peptides were at with in MS analysis The MS/MS and the search showed acid of to acid in this in of the a of the peptide (m/z was from the sample eluted in the of by IGEL method and The of to the peptide with was hardly in that contamination in F reaction with be for the mass analysis. the MS/MS from the showed the of the The iTRAQ ions in the MS/MS of and that or peptide was in lung cancer which was with that the relative of eight ions was not by the use of elution and the IGEL method have a great for the identification of glycosylation sites on of such as serum Moreover, the use of 8-plex iTRAQ enabled the relative quantification of glycan structures on each glycosylation We applied this method to the screening for the glycan structure alterations in lung cancer sera. we the quantification analysis of is to be of the that the quantification analysis using peptides can be by their affinity changes to the lectin column and by the of their protein the effect of protein and the glycan structure we LC/MS/MS of peptides without lectin-column as well as the sample lectin- column the identification of glycopeptides from peptides were identified with from MS/MS the and peptides with identification or the we identified peptides including peptides The enrichment of glycopeptides using was had great in that the of was and the peptide quantification were with the peptide the search results by a of such as of of of on a we the using the the of the on 107 peptides with the N-glycosylation is of the 12 peptides had at that not the N-glycosylation sites were on which were to serum proteins LC/MS/MS analysis on samples identified serum proteins and 50 proteins them were in the of the glycopeptides identified from which were to glycopeptides of glycopeptides that IGEL identified from only samples. six proteins which were identified from only samples were not to be applied to the quantification analysis of the of the protein concentration from lectin a serum R. M. J. Clin. Med. PubMed Scopus Google Scholar) These significant of the detection of mass analysis by the enrichment of IGEL we site-directed variations of the glycan structures on each of relative quantification using 8-plex iTRAQ the of the ions from eight samples (m/z and was by the of three controls (m/z and and the affinity variations to lectin eight samples were as The of the relative changes of the identified glycopeptides eight serum samples were in glycopeptides to and showed affinity change to lectin in lung cancer sera. identify glycosylation sites on which the glycan structures in lung we peptides the two (1.Wollscheid B. Bausch-Fluck D. Henderson C. O'Brien R. Bibel M. Schiess R. Aebersold R. Watts J.D. Nat. Biotechnol. 2009; 27: 378-386Crossref PubMed Scopus (429) Google Scholar) the affinity to lectin showed more than twofold change in three lung cancer sera, with the normal and S.M. Smith D.M. Alt N. Thorpe S.R. Baynes J.W. Ann. N.Y. Acad. Sci. 2005; 1043: 817-823Crossref PubMed Scopus (29) Google Scholar) the in the between the and and the lung cancer and was than This identified eight glycopeptides as for serum glycan biomarkers of lung cancer and six peptides showed more than twofold affinity to lectin in lung cancer sera with normal two peptides showed than affinity to lectin in lung cancer sera. We 1 protein 1 and as carbohydrate-targeting glycan structure changes were specific to three lung cancer sera. The MS/MS spectra to the were in We changes in the relative of each between the samples lectin-column and for of the relative of the in samples the of the identified protein the protein concentration in from the peptide quantification results of samples in glycosylation changes be Thus, lung of the affinity to lectin was for three glycopeptides and significant was for of glycopeptides more than affinity change to lectin in lung cancer in were We the peptide identification as identified N-glycosylation sites were by and their acid were also change of the affinity to lectin were as relative from the of three normal samples The ratio of more than or than change was in or change of the affinity to lectin were as relative from the of three normal samples The ratio of more than or than change was in or change of the affinity to lectin were as relative from the of three normal samples The ratio of more than or than change was in or change of the affinity to lectin were as relative from the of three normal samples The ratio of more than or than change was in or change of the affinity to lectin were as relative from the of three normal samples The ratio of more than or than change was in or change of the affinity to lectin were as relative from the of three normal samples The ratio of more than or than change was in or change of the affinity to lectin were as relative from the of three normal samples The ratio of more than or than change was in or change of the affinity to lectin were as relative from the of three normal samples The ratio of more than or than change was in or on on on on on on on on The in were We the peptide identification as The identified N-glycosylation sites were by and their acid were also change of the affinity to lectin were as relative from the of three normal samples The ratio of more than or than change was in or in a new MS/MS spectra of biomarker The whole of MS/MS of identification in and peptide identification are for and The or show peptide identification from or lectin-column samples or ions to three healthy controls, two samples and three lung cancer samples were with and to of in the sera of lung cancer patients further in the of human sera using a sera from and of healthy volunteers patients or lung cancer patients or were by and the of in the sera was by as was a of in the sera between the sera and the lung cancer sera. was in the lung cancer sera by lectin column were in of the two of the or lung cancer and of the lung cancer samples. we the eight samples used in the screening by the to in for this study and that the quantitative of eight samples was with the of iTRAQ quantification the screening and this showed affinity of to lectin on the iTRAQ lung cancer These results that in lung cancer sera. the sample was the results were and the of this and MS allow the measurements of at M. Aebersold R. Mol. 2009; PubMed Scopus Google Scholar), glycoprotein or enrichment is to detection and identification of in and of biological We have only to or glycopeptides such as lectin to specific glycan structures Y. Y. S. Aebersold R. Zhang H. Nat. Protoc. 2007; PubMed Scopus Google Scholar, S. V. M. 2007; 21: PubMed Scopus Google Scholar), and J. K. Methods Mol. Biol. 2009; 534: Google Scholar). of their to a of and their are most used for the of the enrichment of and biomarker Our IGEL can a great deal to the of complicated of quantitative and of for the we identified serum proteins from the sample in this method a of serum and the elution from the lectin highly specific of glycopeptides was with elution of and the elution efficiency on the glycan structures the of on a Moreover, is to the of lectin-column chromatography interactions are with interactions and the efficiency can by or elution The combination of the of IGEL and the use of 8-plex iTRAQ quantitative caused by our using conventional lectin-column chromatography and immunoblot analysis confirmed the quantitative and of These further the of IGEL in enrichment and not only to studies but to diverse of studies and clinical lectin structure including which in the Y. Kasai K. H. Y. J. Biol. PubMed Google Scholar). is also that the of structure its affinity to for on the glycosylation sites identified in our screening be that the of N-glycosylation or addition of structure was in lung cancer sera. The can be to various of and eluting which more comprehensive analysis of glycan structure alterations. Our quantification and identification of serum glycopeptides using column and N-glycosidase F In the is also by the sample to × with a in each which provide for high-throughput quantitative analysis for glycan to our and the of 8-plex iTRAQ labeling system were we should that this system to the of peptide Our of column samples identified our using the except for the use of 8-plex iTRAQ labeling identified more than serum proteins not This of identified proteins be caused by the of peptide eight samples by which of serum should be the of such isotope can in quantitative and of peptides be to improve its to the clinical application of disease biomarkers, we should that we have only techniques to the glycan structure changes In is method by which glycan structure variations on a specific glycosylation site can be and quantitatively for of samples. We show that our screening to the of diverse glycan but new technologies are that the glycoproteomic profiling results lead to clinical as or biomarkers in the We and at Applied for their with

References

8